Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain

• Autores principales: Jesús De La Fuente (Autor), Juan José Hernandez Aguado (Autor), María San Martín (Autor), Paula Ramirez Boix (Autor), Sergio Cedillo Gómez (Autor), Noelia López (Autor)
• Formato: Libro
• Publicado: Taylor & Francis Group, 2019-08-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Human papillomavirus (HPV) is one of the main causes of infection-related cancer. The bivalent vaccine (2vHPV) (16/18) and quadrivalent (6/11/16/18) HPV vaccine (4vHPV) have been included in the Spanish vaccination calendar since 2007. The new nonavalent HPV vaccine (9vHPV), approved in Europe in 20...